Beyond these superficial changes, the company will continue to operate as before. Our focus continues to be on bringing our late-stage Phase 3 drugs: nusinersen, volanesorsen and IONIS-TTR
Headquarters:
Australia
Company Type:
SME
Company size:
Employees
Address:
null
LOW
spending power